entity_name,head_count,tail_count,labels
gut microbiota,78,31,"['Biological Component', 'Organism', 'Microbiota', 'microbial community', 'organism', 'Microorganism', 'ecosystem', 'Microbial community', 'microbiota', 'Biological Process', 'Biological Entity', 'biological entity', 'BiologicalEntity', 'biological process', 'Microbial Community', 'Physiological Process', 'Microbial_Community']"
CDR,29,0,['biological process']
gut microbiome,29,8,"['microbial community', 'Biological Data', 'microbiome', 'biological system', 'Biological Process', 'Biological Entity', 'Microbial Community', 'organism', 'Microbiome']"
probiotics,22,0,"['therapy', 'Substance', 'Dietary Factor', 'intervention', 'Food', 'Therapeutic Agent', 'dietary supplement']"
Parkinson's disease,21,19,"['Neurological Disorder', 'disease', 'Disease', 'neurodegenerative disease']"
gut-brain axis,20,4,"['biological system', 'Biological Process', 'Physiological System', 'Biological System', 'Physiological Process']"
post-COVID-19 DGBI,18,0,['Condition']
microbiota,18,5,"['microbiota', 'ecosystem', 'biological entity', 'Biological Entity']"
Dextran Sodium Sulphate,17,0,['Chemical']
Xingpijieyu formula,17,0,['Medicine']
Bugs and Brains Study,16,0,['Study']
Gut microbiota,16,8,"['Microbial Community', 'Organism', 'Biological Entity']"
review,14,4,"['Literature Review', 'Literature', 'literature']"
Melanin,14,0,['Pigment']
secondary outcomes,14,0,['Outcome']
Bacillus licheniformis,13,1,['Probiotic']
High-fiber diet,12,0,['Diet']
EDF group,11,0,['Treatment Group']
Probiotics,11,4,"['Therapeutic Agent', 'Biological Agent', 'Intervention']"
Hydrogen Sulfide,11,0,['Chemical']
MEs,11,0,['Molecule']
Triphala polyphenols,10,0,['Botanical Supplement']
patients,10,2,"['HumanSubject', 'group', 'Patient Population']"
neurological and mental disorders,10,4,['disease']
failure in interaction,10,0,['biological process']
probiotic supplementation,9,1,"['Treatment', 'treatment', 'therapeutic intervention', 'Intervention']"
Malnutrition,9,0,['Condition']
microbiota-gut-brain axis,9,2,"['Biological System', 'Biological Process', 'Biological Axis']"
ED group,9,0,['Treatment Group']
Gut Microbiota,9,5,"['Biological System', 'Organism', 'Biological Entity']"
Lactobacillus reuteri ATG-F4,8,0,['Probiotic']
Probiotic NVP-1704,8,0,['Probiotic']
factors influencing microbiota analysis,8,0,['Influencing Factors']
study,8,1,"['Research', 'ResearchStudy', 'Research Study']"
Fermented Wheat Germ,8,0,['Substance']
metabolites,8,1,"['metabolites', 'Substance']"
Butylated Starch,7,0,['Substance']
Ruminococcaceae,7,0,"['Microbial Family', 'Taxa']"
dysbiosis,7,0,"['microbial imbalance', 'Microbial Imbalance', 'Physiological State']"
Autoimmune diseases,7,2,['Disease']
Large-scale cohorts,7,0,['Study']
Lactobacillus plantarum CCFM8661,7,0,['Probiotic']
Gut Microbiome,7,1,"['Organism', 'Biological Entity']"
participants,7,0,"['Population', 'Human']"
Parkinson's disease (PD),7,9,['Disease']
Microbiome,6,0,['Biological Entity']
gut dysbiosis,6,8,"['Condition', 'Microbial Imbalance', 'Microbiota', 'biological process']"
changes in gut microbiota,6,0,['biological change']
aging,6,1,"['process', 'Biological Process']"
Firmicutes,6,1,"['Organism', 'Microbial Phylum']"
Bacteroides,6,1,"['Bacterial Genus', 'Organism', 'Bacteria', 'Microbial Genus']"
Changes in microbiota composition,6,0,['Change']
High-cholesterol diet,6,5,['Diet']
microflora metabolites,6,0,['chemical_substance']
FD mice,6,3,['Animal model']
phytochemicals,6,9,['substance']
canine intestinal microbiota,5,0,['Physiological Process']
PCOS-DP,5,4,['Patient Group']
Probiotic group,5,0,['Group']
complex landscape,5,1,['Concept']
AGPs,5,1,['Substance']
Dysregulation of Gut Barrier Functions,5,2,['Physiological Process']
Gut microbiome,5,0,"['Biological System', 'Biological Entity']"
Toll-like receptor 4,5,0,['Protein']
Neurodegenerative diseases,5,0,['Disease']
Essential oils,5,0,['Substance']
inflammatory markers,5,3,"['Biological Molecule', 'Measurement', 'Biological Marker']"
prebiotic supplementation,5,0,['treatment']
Within-Subject Dissimilarities,5,0,['Measure']
Probiotic supplementation,5,0,['Behavior']
Toll-like receptor 2,5,0,['Protein']
protocol,5,0,['Protocol']
Affective disorders,5,2,['Disease']
bin_55,5,0,['Microbial Strain']
subdiaphragmatic vagotomy,5,0,['Medical procedure']
dietary transition,5,0,['dietary change']
research,5,1,"['activity', 'Research Activity', 'Research Field']"
patients after SG,4,0,['group']
microbiota changes,4,0,['Biological Change']
gut-microbiota-brain axis,4,2,"['biological system', 'Physiological system']"
Haemophilus,4,0,['Bacteria']
long-term acetate deficiency,4,0,['Metabolic Condition']
Insomnia,4,4,['Mental Health Issue']
patients with alcohol overconsumption,4,0,['Patient group']
anxiety disorders,4,2,"['Condition', 'mental disorder', 'disease']"
Major depression,4,1,['Disease']
Parkinsonian pathology,4,1,['Pathological process']
Shotgun metagenomics,4,0,['Method']
Lactobacillus fermentum PS150,4,2,['Bacteria Strain']
potential psychobiotics,4,0,['Microbiota']
Triphala,4,0,['Herbal Medicine']
vitiligo,4,1,['Disease']
four potential psychobiotics,4,0,['Microbiota']
Colon cancer-related anemia (CCRA),4,0,['Medical Condition']
Akkermansia_muciniphila,4,0,['Microbial Species']
disruption of intestinal integrity,4,0,['Pathological Process']
SBF,4,1,['Chemical']
Diseases,4,0,['Disease category']
Alzheimer's disease,4,6,"['Neurological Disorder', 'disease', 'Disease', 'neurodegenerative disease']"
PD patients,4,1,['Patient']
underlying factors,4,1,['Factor']
Berberine,4,0,['Substance']
human microbiome,4,0,['Microbial Community']
prebiotics,4,0,"['Therapeutic Agent', 'dietary supplement', 'Food']"
intestinal microbiota,4,0,['Physiological Process']
diet,4,2,"['Nutrition', 'Dietary Factor', 'Factor']"
Depression,4,8,"['Mental Health Condition', 'Disease', 'Mental Disorder']"
Bifidobacterium,4,1,"['Bacteria', 'Microbial Species', 'Bacterial Genus']"
Lactobacillus,4,2,"['Organism', 'Taxonomic Group', 'Bacteria', 'Bacterial Genus']"
Blautia,4,1,"['Bacteria', 'microbial genus', 'Microbial Species']"
therapeutic strategies,4,1,['concept']
preventive strategies,4,1,['concept']
chronic insomnia patients,4,2,['Patient Group']
acute insomnia patients,4,2,['Patient Group']
gut microbiota composition,4,3,"['Condition', 'Biological Entity', 'biological entity', 'Biological Composition']"
usage of pesticides,4,0,['agricultural practice']
Mediterranean diet,4,0,['Diet']
Schizophrenia,4,8,['Disease']
studies,3,1,"['activity', 'Research Study', 'research']"
Fiber-deficient diet,3,0,['Dietary factor']
stool samples,3,2,"['Samples', 'Sample', 'Sample Type']"
VSL #3,3,0,['Probiotic']
tryptophan,3,2,"['Amino Acid', 'Chemical']"
microbiota composition,3,3,"['Biological Process', 'Microbiome']"
Host metabolites,3,1,['Metabolite']
Shotgun metagenomics sequencing (SMS),3,0,['Method']
RSDS Mice,3,0,['Animal Model']
short-chain fatty acids,3,4,"['Biochemical', 'Chemical', 'metabolite', 'Chemical Entity']"
cuprizone,3,0,['Chemical']
microbial metabolites,3,0,['chemical_substance']
maternal vaginal microbiota,3,0,['microbiota']
Pharmacomicrobiomics,3,0,['Scientific Field']
Irritable bowel syndrome (IBS),3,0,['Disease']
Christensenellaceae,3,1,['Microbial_Family']
Seabuckthorn,3,1,['Plant']
gut permeability,3,0,['BiologicalProcess']
psychosocial factors,3,0,['Factor']
prebiotic diet,3,0,['diet']
brain-gut axis,3,0,['biological system']
postbiotics,3,1,"['Therapeutic Agent', 'Substance']"
microbial dysbiosis,3,0,['Condition']
Prevotella,3,0,"['Organism', 'Bacteria', 'Bacterial Genus']"
Trichloroethylene,3,0,['Chemical']
intermittent fasting,3,1,['Intervention']
RNA-seq,3,0,['Method']
antibiotic use,3,0,['treatment']
diets,3,0,['Diet']
Lewy Body Dementia,3,1,['Disease']
amino acid metabolism pathways,3,1,['Pathway']
functional changes,3,1,['Effect']
phylum Proteobacteria,3,1,['Taxonomic Group']
Gut microbiome changes,3,0,['Biological Process']
ageing process,3,2,['Biological Process']
changes in certain taxa,3,0,['Biological Process']
neuroactive compounds,3,0,['Chemical']
pathways,3,1,['BiologicalPathway']
Olanzapine,3,0,['Substance']
Repeated Social Defeat Stress,3,0,['Stress Model']
targeting microbiome,3,0,['Therapeutic Strategy']
AGP-induced changes,3,0,['Effect']
vancomycin exposure,3,0,['Exposure']
cell danger response,3,0,['biological process']
China,3,0,"['Country', 'country']"
future directions,3,1,['concept']
Defects of Firmicutes,3,0,['Microbial Deficiency']
balanced diet,3,0,['diet']
chronic diseases,2,1,['Disease']
Bacteroidetes,2,0,"['Microbial Phylum', 'Bacterial Phylum']"
Co-morbid GI inflammation,2,0,['Condition']
Posttraumatic Stress Disorder (PTSD),2,0,['Mental Health Condition']
GI inflammation,2,1,['Condition']
gut microbiota signatures,2,0,['Microbial Community']
Boruta algorithm,2,0,['Algorithm']
patients' mental functioning,2,0,['condition']
shotgun metagenomic sequencing,2,0,"['Method', 'Sequencing Method']"
Beneficial effect,2,0,['Effect']
neuroinflammation,2,3,"['process', 'Biological Process', 'Pathological Process', 'Pathological condition']"
Intestinal microbiome,2,0,['Biological Entity']
Dietary fiber deficiency,2,0,['Dietary factor']
oral microbiota imbalance,2,0,['condition']
oral bacteria,2,1,['microorganism']
findings,2,0,['Research Findings']
Compositional alterations,2,0,['Change']
microbiome crosstalk,2,1,['Biological Interaction']
Stress,2,0,['Condition']
article,2,0,['publication']
K01626,2,0,['KEGG Orthology']
flu,2,0,['illness']
Probiotic consumption,2,0,['Behavior']
Dysregulation,2,0,['Physiological Process']
Gut microbial changes,2,0,"['Microbial Changes', 'Biological Process']"
USA,2,0,['country']
relative abundance,2,1,['Property']
IBS,2,2,"['Condition', 'Disease', 'disease']"
Functional genes,2,0,['Genetic Element']
bipolar disorder,2,3,"['disease', 'Disease']"
FD diet,2,0,['Dietary factor']
disturbances,2,0,['condition']
further research,2,1,['research']
future research,2,0,['Research Activity']
Danggui Buxue Decoction (DBD),2,0,['Herbal Medicine']
maternal rectal microbiota,2,0,['microbiota']
altered gut microbiome,2,2,"['Biological Process', 'Biological State']"
RF classification,2,0,['Model']
Genes Correlated with Gut Microbiota,2,0,['Gene Expression']
Dysbiosis,2,1,['Pathological Condition']
Intestinal Luminal Contents,2,1,['Biological Material']
mental health symptoms,2,0,"['Symptom', 'symptom']"
Akkermansia,2,0,"['Bacteria', 'Microbial Species']"
Increase in fiber intake,2,0,['Nutritional strategy']
Cognitive impairment,2,0,['Disease']
biological aging,2,2,['Biological Process']
Intestinal Epithelial Cells,2,0,['Cell Type']
Norepinephrine,2,1,['Neurotransmitter']
microglial activation,2,2,"['cellular activity', 'Pathological process']"
Fiber-deprived diet,2,0,['Dietary factor']
Bioactive polyphenols,2,0,['Micronutrient']
faecal samples,2,2,['Sample']
targeted therapeutic strategies,2,1,['therapy']
Alterations of microbes,2,0,['Trait']
Dietary modifications,2,0,['Intervention']
SCFA,2,0,"['Substance', 'Biochemical compound']"
maternal immune activation,2,1,['phenomenon']
endogenous processes,2,1,['Biological Process']
Romboutsia,2,0,['microbial taxon']
tryptophan transport,2,1,['transport process']
running exercises,2,0,['activity']
Crude Extract containing EPS (C-EPS),2,0,['Biological Extract']
Tremors predominant phenotype,2,0,['Phenotype']
metabolic memory,2,0,['biological memory']
Gut Commensal Bacteria,2,0,['Microbial Entity']
western diet,2,0,['diet']
Multiple sclerosis,2,0,['Disease']
serum SCFA content,2,0,['Biological Molecule']
Human Gut Microbiomes,2,0,['Organism']
antimicrobial resistance,2,1,['Concept']
Differential Expressed Genes,2,0,['Gene Expression']
Dialister,2,0,['Microbial Species']
Disturbance,2,0,['Condition']
HbA1c,2,1,['Biological Marker']
Alterations in the gut microbiome,2,2,['Biological process']
Parkinson's Disease,2,3,['Disease']
Influenza Infections,2,0,['Disease']
antidepressant drugs,2,0,['Substance']
small intestine,2,0,['Anatomical Structure']
chronic gut dysfunction,2,2,['Condition']
Gut Microbiome Modifications,2,1,['Process']
Repeated Social Defeat Stress (RSDS),2,0,['Stress Model']
Acetylated Starch,2,0,['Substance']
food processing,2,0,['Process']
fermented foods,2,1,['Food']
Stool Samples,2,2,['Sample']
patients after RYGB,2,0,['group']
Lachnospiraceae,2,1,"['Bacterial Family', 'Microbial Family', 'Taxa']"
Neuroactive compounds,2,0,['Chemical']
nutritional approaches,2,2,['concept']
future long-term human space expeditions,2,1,['Expedition']
animal experiments,2,0,['Experiment']
vancomycin,2,0,['Antibiotic']
Turicibacter,2,1,['microbiota']
AD,2,0,['Disease']
future studies,2,0,['Research Study']
decreased microbial diversity,2,0,['Biological Process']
herpesvirus,2,4,['Virus']
Megamonas,2,0,"['Bacterial Genus', 'Microbial Species']"
birds,2,0,['Organism']
taxa,2,0,['Taxonomic Group']
perturbation of gut microbiota,2,0,['biological disturbance']
Lactobacillus fermentum GR1009,2,0,['Bacteria Strain']
CSF1R inhibitor,2,0,['pharmacological agent']
altering gut microbiota,2,0,['Therapeutic Strategy']
LBD,2,0,['Disease']
PD,2,0,['Disease']
next-generation feed additives,2,1,['Substance']
oral microbiota,2,0,['Biological Process']
Flavonifractor,2,1,['Microbial_Genus']
medicinal herbs,2,0,['therapy']
Chronic Mild Stress,2,0,['Stress Model']
enteric and brain barrier reinforcement,2,2,['concept']
sensing and trafficking modulation,2,2,['concept']
Clostridium,2,0,"['Taxonomic Group', 'microbial genus']"
Sanada et al. (2020),2,0,['Research Study']
Healthy diet,2,0,['Diet']
improvement in gut microbiota,2,0,['BiologicalProcess']
Coprococcus 1,2,1,['microbiota']
Non-probiotic interventions,2,0,['Intervention']
Psychological health risk,2,0,['Risk']
Individuals affected by NDD,2,0,['Population']
Eggerthellaceae,2,1,['microbiota']
metabolic products of dysregulated bacteria,2,0,['biological product']
Caloric restriction,2,0,['Intervention']
microbiome manipulations,2,2,['concept']
Maternal prenatal gut microbiota,2,0,['Microbiota']
unbalanced dietary intake,2,6,['diet']
altered microbiota,2,0,['Organism']
neuroanatomy,2,1,['biological structure']
maternal faecal microbiota,2,0,['Microbiota']
demyelination,2,4,['Pathological process']
Regular exercise,2,0,['Activity']
schizophrenia,2,5,"['Neurological Disorder', 'disease']"
inflammation,2,13,"['Biological Process', 'BiologicalProcess', 'Biological process', 'Pathological Process']"
melanin levels,2,3,['Pigment level']
further understanding,2,0,['concept']
translational research,2,1,['Research Field']
acute/chronic insomnia-related signature bacteria,2,0,['Bacteria']
meditation,2,0,['Practice']
PICRUSt analysis,2,0,"['Method', 'bioinformatics tool']"
Polycystic ovarian syndrome,2,0,['Disease']
Coprococcus,2,0,"['Bacteria', 'microbial genus']"
Faecalibacterium,2,0,"['Bacteria', 'Bacterial Genus']"
Lachnospira,2,0,"['Bacteria', 'Microbial Species']"
Klebsiella,2,1,"['Bacteria', 'microbial genus', 'Taxonomic Group']"
α-synuclein overexpressing mice,2,0,['animal model']
insomnia symptomology,2,0,['Symptom']
N-acylphosphatidyl ethanolamines (NAPEs),2,0,['Lipid']
time to complete the Stroop-C,2,1,['Cognitive Test Metric']
Rodent Models,2,0,['Rodent Models']
danger signals,2,0,['signal']
migraine,2,5,"['Neurological Disorder', 'MedicalCondition']"
Multiomics study,2,1,['Research Method']
gut microbiota changes,2,0,"['Biological Entity', 'Microbial Adjustment']"
Flavonoids,2,1,['Chemical']
prebiotic feeding,2,0,['dietary intervention']
gut microbiome composition alterations,2,0,['Biological Process']
association,2,2,"['Relationship', 'concept']"
bin_32,1,1,['Microbial Strain']
duodenal aspirates,1,0,['Sample Type']
gut microbiota shifts,1,0,['Biological Process']
metabolism,1,1,"['biological_process', 'Biological Process']"
increased relative abundance,1,1,['Biological Process']
abnormal intestinal metabolites,1,0,['chemical_substance']
K01667,1,0,['KEGG Orthology']
colonic microbiota,1,0,['Microbiota']
gnotobiotic murine model,1,0,['Model']
coronavirus disease (COVID)-19,1,0,['Disease']
thyme,1,1,['Plant']
GI infections,1,0,['Infection']
severe acute respiratory syndrome coronavirus-2 (SARS-CoV2),1,0,['Virus']
Gut Bacteria,1,1,['Organism']
Zhejiang University,1,0,['Institution']
Shaohua Hu,1,0,['Author']
autonomic nervous system dysregulation,1,0,['physiological state']
trimethylamine N-oxide,1,0,['Biochemical']
Lactobacillus genus,1,0,['MicrobialGenus']
glutamic acid,1,1,['Chemical']
Autism Spectrum Disorder,1,1,['Disease']
HPA axis,1,0,['biological system']
oregano,1,1,['Plant']
immune routes,1,1,['biological process']
cardiac tissue proteome,1,0,['Proteome']
protein oxidation,1,0,['BiologicalProcess']
vagus nerve,1,1,"['Anatomical Structure', 'Anatomical structure']"
subjects,1,0,['Population Group']
CCDC173,1,0,['Gene']
microbial tryptophan metabolism,1,1,['metabolic process']
migraine headache,1,0,['MedicalCondition']
metabolic mismatch,1,1,['biological state']
Toll-like receptor 2 signaling pathways,1,1,['Physiological Process']
Ruminococcaceae Incertae Sedis,1,1,['Organism']
patients with depression,1,0,['Patient Group']
Gut Microbiota Taxa,1,1,['Biological Entity']
Mental Illnesses,1,0,['Mental Health Condition']
Gut microbiome alterations,1,0,['Biological process']
Gut-Brain Axis,1,2,"['Biological Entity', 'Physiological Axis']"
gut microbiota-derived metabolites,1,0,['metabolites']
Frontiers in Psychiatry,1,0,['Journal']
Toll-like receptor 4 signaling pathways,1,1,['Physiological Process']
Multiple Sclerosis,1,0,['Neurological Disorder']
Influenza Virus Infection,1,0,['Infectious Disease']
primary outcome,1,0,['Outcome']
prebiotic high-fiber diet,1,0,['diet']
specific probiotics,1,0,['Intervention']
Host Gene Regulation,1,1,['Biological Process']
Desulfovibrionaceae,1,0,['Organism']
Toll-like receptors,1,0,['Protein']
ratios of meat to pulses,1,0,['diet component']
Butyrate,1,0,['Substance']
fermenting dietary fibers,1,1,['Process']
exogenous acetate supplement,1,0,['Therapeutic Intervention']
16S rRNA sequencing,1,1,"['method', 'technique']"
decreased diversity,1,0,['Biological Process']
Enterococcus,1,0,['Taxonomic Group']
Escherichia,1,0,['Taxonomic Group']
Bilophila,1,0,['Taxonomic Group']
Chronic unpredictable mild stress (CUMS),1,0,['Stress Model']
cognitive symptoms,1,0,['Symptom']
plagues,1,0,['Pathological feature']
Random Forests (RF) classification,1,0,['Classification Method']
melanomas,1,0,['Disease']
DNA damage,1,0,['Factor']
usage of fertilizers,1,0,['agricultural practice']
Amyotrophic lateral sclerosis,1,0,['Disease']
Viral infections of the brain,1,0,['Infection']
brain,1,7,"['Anatomical Structure', 'organ', 'Tissue type', 'biological organ', 'Organ', 'Biological Entity']"
inflammation in the brain,1,1,['Biological process']
farming density of pigs,1,0,['agricultural practice']
Energy from ATP,1,0,['Energy source']
SARS-CoV2 infection,1,0,['Infection']
melanin,1,0,['Pigment']
A. muciniphila,1,1,['microbial taxon']
increase in alcohol intake,1,0,['diet component']
meta-analysis,1,1,['Statistical Method']
16S rRNA gene sequencing,1,2,"['Method', 'Technique']"
Vasovagal syncope,1,0,['Medical Condition']
participant,1,0,['Human']
Microbiota-gut-brain dysfunction,1,0,['Physiological Dysfunction']
V4 16S rRNA gene sequencing,1,0,['Sequencing Method']
Lachnoclostridium,1,2,['Genus']
rodent models,1,0,['Rodent Models']
pro-inflammatory state,1,0,['Physiological State']
16S ribosomal RNA analysis,1,0,['Lab test']
Serum and brain metabolite concentrations,1,1,['Metabolite Concentrations']
Tryptophan metabolism,1,2,['Metabolism']
patients with COVID-19,1,0,['Patient Population']
Colorectal cancer,1,3,['Disease']
Jun Yu,1,0,['Researcher']
Bibliometric methods,1,0,['Research Methodology']
Specific microorganisms,1,0,['Microbial Species']
body-first progression,1,2,['Progression Type']
brain-first progression,1,2,['Progression Type']
individuals,1,0,['Population']
Modification of the gut microbiota,1,0,['Biological Process']
untargeted metabolomic analysis,1,0,['Lab test']
Abnormal microbiota,1,0,['Microbial Community']
Antidepressant medications,1,1,['Medication']
Chronic consumption of Lactobacillus reuteri ATG-F4,1,0,['Probiotic Treatment']
Htr1a,1,1,['Gene']
Restoring gut microbiota,1,0,['Therapeutic Intervention']
age-related upward pattern,1,1,['trend']
schizophrenia severity,1,0,['disease_state']
evidence,1,0,['scientific evidence']
third hierarchical level of KEGG pathways,1,0,['Pathway Level']
Alterations in gut microbiota,1,0,['Biological Change']
overactive hypothalamic-pituitary-ovarian and hypothalamic-pituitary-adrenal axes,1,0,['Physiological Process']
micronutrient supplementation,1,0,['Dietary Factor']
abnormal levels of neurotransmitters,1,0,['Biochemical Abnormality']
leucine,1,0,['Metabolite']
epiandrosterone sulfate,1,0,['Metabolite']
3-dehydrocarnitine,1,0,['Metabolite']
targeting the gut microbiome,1,0,['therapeutic strategy']
genus_Eggerthella,1,0,['Microbial Taxon']
genus_Coprococcus2,1,0,['Microbial Taxon']
Family_Ruminococcaceae,1,0,['Microbial Taxon']
CT-26,1,0,['Cell Line']
DNA methylation,1,0,['Epigenetic Mechanism']
data science techniques,1,0,['Methodology']
Gut microbiota modulation,1,0,['Therapeutic Strategy']
central nervous system (CNS),1,1,['nervous system']
Downregulation of Htr1a,1,0,['Gene Expression Change']
AAV-shRNA,1,0,['Gene Editing Tool']
Maintaining gut microbiota,1,0,['Therapeutic Intervention']
Traditional depression treatments,1,0,['Treatment']
world,1,0,['global']
genus_Eubacterium (xylanophilum_group),1,0,['Microbial Taxon']
Metabolites,1,0,['Biological Entity']
Obstructive Sleep Apnea,1,11,['Disease']
Ruminococcus-2,1,0,['Bacteria']
changes in human health,1,1,['Biological Process']
Inflammatory bowel disease,1,0,['Disease']
Anaerostipes,1,0,['Bacteria']
Fusobacterium nucleatum,1,0,['Microbial Species']
Bile acids,1,0,['Biochemical Compound']
16s rRNA sequencing technique,1,0,['Sequencing Method']
Random Forest classifier,1,0,['Machine Learning Model']
Gut Microbiota-associated Epitopes,1,0,['Molecule']
genus level of taxonomy,1,0,['Taxonomic Level']
Correcting microbiota disturbances,1,0,['Therapeutic Intervention']
Eyes Absent Homolog 1 Isoform 4 (EYA1),1,0,['Protein']
Paired Box Protein Pax-3 (PAX3),1,0,['Protein']
Gap Junction Alpha-1 (GJA1),1,0,['Protein']
post-COVID-19 IBS,1,1,['Condition']
CREB3L3,1,0,['Gene']
Web of Science Core Collection,1,0,['Database']
Lipid Metabolism Pathways,1,0,['Biological Pathway']
gut microbial,1,0,['microbial community']
K11358,1,0,['KEGG Orthology']
baseline changes in microbiota,1,0,['Biological Change']
Random Forests (RF) algorithm,1,0,['Algorithm']
role of host microbiota,1,1,['concept']
gut microbiota alterations,1,0,['Alteration']
Listeriolysin O Peptide,1,0,['Molecule']
oxaliplatin,1,0,['Chemotherapy Drug']
CiteSpace,1,0,['Software Tool']
Parabacteroides,1,1,"['Organism', 'Bacteria']"
GABA,1,1,['Neurotransmitter']
treatment-emergent changes in microbiota,1,0,['Biological Change']
Journal of Psychiatric Research,1,0,['Journal']
Evans,1,0,['Author']
ratios of poultry meat to pulses,1,0,['diet component']
fecal microbiota transplant,1,0,['Therapeutic Intervention']
Gut dysbiosis,1,0,['Condition']
Mice,1,0,['Rodent Models']
Healthcare systems,1,0,['System']
genus_Ruminococcaceae (UCG009),1,0,['Microbial Taxon']
microbial tryptophan (Trp) biosynthesis and metabolism pathway,1,0,['Pathway']
Chronic unpredictable stress (CUS),1,0,['Stress Model']
5-HT receptor HTR2A,1,0,['Receptor']
5-HT,1,1,['Neurotransmitter']
IL-17A,1,1,['Cytokine']
MCP-1,1,1,['Cytokine']
metabolic changes,1,1,['Metabolic Process']
gut microbiota composition alteration,1,0,['Microbiome Change']
K01817,1,0,['KEGG Orthology']
Actinobacteria,1,0,['Bacterial Phylum']
VOSviewer,1,0,['Software Tool']
gut microbe,1,1,['Microbial Community']
genus_Subdoligranulum,1,0,['Microbial Taxon']
MiTBamp,1,0,['Pathway']
Succinivibrio,1,0,['microbial genus']
apolipoprotein B,1,0,['Biochemical Index']
Tibetan Buddhist meditation,1,0,['Practice']
TNFα,1,0,['Protein']
IFNγ,1,0,['Protein']
Dysbiosis of intestinal microbiota,1,0,['Condition']
Regulating intestinal microbiota,1,2,['Therapeutic Strategy']
current study,1,0,['Research Study']
Genomic signatures,1,0,['Genomic Feature']
Fucose permease (COG0738),1,0,['Transporter']
infant's nasal microbiota,1,0,['microbiota']
infants born by Caesarean section,1,0,['infant']
feeding mode,1,0,['feeding']
neonatal period,1,0,['Time Period']
Random Forests (RF),1,0,['Algorithm']
classification model,1,2,['Model']
KEGG orthology (KO) K01696,1,0,['Gene Orthology']
gastrointestinal symptoms,1,3,"['Symptom', 'gastrointestinal symptom']"
formation pathways,1,0,['Process']
potential health effects,1,0,['Health']
Elevated Plus Maze,1,0,['Behavioral Test']
Forced Swim Test,1,0,['Behavioral Test']
faecal microbiota,1,0,['Microbiota']
prenatal diet,1,0,['Diet']
Proteobacteria,1,0,['microbial phylum']
Megasphaera,1,0,['microbial genus']
Collinsella,1,0,['microbial genus']
vitamin B6,1,0,['metabolic pathway']
Interferon-γ,1,0,['Cytokine']
Tumor Necrosis Factor-α,1,0,['Cytokine']
"Indoleamine 2,3-Dioxygenase-1",1,0,['Enzyme']
Microbiota,1,0,['Gut Microbiota']
healthy prenatal diet,1,0,['Diet']
alpha diversity of maternal faecal microbiota,1,0,['Microbiota Diversity']
Faecalibacterium spp.,1,0,['Bacteria']
Coprococcus spp.,1,0,['Bacteria']
Short-term FD diet,1,0,['Dietary factor']
Gut microbiota profile,1,0,['Microbial community']
Hippocampal synaptic ultrastructure,1,0,['Organ part']
Synaptic clefts,1,0,['Anatomical structure']
Blautia spp.,1,0,['Bacteria']
Phylum Bacteroidetes,1,0,['Taxonomic Group']
Prevotellaceae,1,0,['Bacteria']
Fecal Microbiota,1,0,['Biological Entity']
KEGG orthology (KO) K00382,1,0,['Gene Orthology']
KEGG orthology (KO) K00626,1,0,['Gene Orthology']
Postsynaptic densities,1,0,['Anatomical structure']
Hippocampal proteomic analysis,1,0,['Biological process']
CaMKIId,1,1,['Protein']
Microglia,1,0,['Cell type']
Prevotella spp.,1,0,['Bacteria']
Phylum Actinobacteria,1,0,['Taxonomic Group']
Microbiome Stability,1,0,['Biological Stability']
6 species,1,0,['Taxonomic Group']
KEGG orthology (KO) K00658,1,0,['Gene Orthology']
KEGG orthology (KO) K00837,1,0,['Gene Orthology']
Oral Probiotics,1,0,['Therapeutic Agent']
Methanobrevibacter,1,0,['microbial genus']
Six-Week Treatment,1,0,['Treatment Period']
interactions between bacterial species,1,0,['Interaction']
Verrucomicrobia,1,1,['Organism']
obesity,1,2,"['medical condition', 'disease', 'Disease']"
12 significant microbiota biomarkers,1,0,['biomarkers']
gut microbial composition,1,0,['Physiological Process']
fatty acid,1,0,['metabolic pathway']
sample collection,1,0,['Method']
sample analysis,1,0,['Method']
high taxonomic resolution,1,1,['Resolution']
Fecal Microbiota Samples,1,0,['Sample']
Omega-3 fatty acids,1,0,['Micronutrient']
Roseburia,1,1,"['microbial species', 'microbial genus']"
Subdoligranulum,1,2,"['Organism', 'microbial species', 'Microbial Species']"
consumption of whole grain cereals,1,0,['dietary intake']
consumption of simple sugars,1,0,['dietary intake']
consumption of SFA,1,0,['dietary intake']
consumption of monounsaturated fatty acids,1,0,['dietary intake']
LEfSe,1,0,['Method']
Traumatic brain injury,1,0,['Injury']
Genetic variability,1,0,['Factor']
Epigenetic changes,1,0,['Factor']
Oxidative stress,1,0,['Factor']
Nitrosative stress,1,0,['Factor']
Mitochondrial dysfunction,1,0,['Factor']
current research,1,0,['research']
Metabolic Pathways,1,1,['Biological Process']
ratios of eggs to pulses,1,0,['diet component']
diet quality,1,0,['diet component']
increase in total calorie intake,1,0,['diet component']
vagal inhibition,1,0,['Intervention']
vagotomy,1,0,['Surgical Procedure']
microbiota metabolite acetate,1,0,['Metabolite']
human body,1,0,['organism']
bariatric surgery,1,0,['medical procedure']
dietary fibers,1,0,['dietary component']
consumption of vegetables,1,0,['dietary intake']
KEGG Analysis,1,0,['Method']
bin_31,1,1,['Microbial Strain']
mental health,1,10,"['Health', 'psychological state', 'Health Condition', 'condition', 'Health Aspect', 'Health Outcome', 'Outcome Measure']"
improved eating habits,1,0,['intervention']
differences in gut microbiota composition,1,0,['biological entity']
45% of 200 bariatric patients,1,0,['group']
Gut-brain pathways,1,0,['Biological Pathway']
Oral microbiota,1,1,['Biological Entity']
changes,1,0,['Biological Process']
Bifidobacterium longum R0175,1,0,['Probiotic Strain']
Sucrose Preference Test,1,0,['Behavioral Test']
anti-inflammatory bacteria,1,1,['Bacteria']
random forest models,1,1,['Model']
Gut-Brain Axis Dysfunction,1,0,['Physiological Dysfunction']
Antidepressants,1,0,['Medication']
Hospital Stay,1,0,['Treatment']
life adversity during childhood,1,0,['environmental factor']
Meditation,1,0,['Practice']
Inpatients,1,0,['Patient Group']
Shannon Index,1,0,['Biodiversity Metric']
Inverse Simpson Index,1,0,['Biodiversity Metric']
Lachnospiraceae FCS020 group,1,0,['microbiota']
Anxiety symptoms,1,1,['Mental Disorder']
long-term deep meditation,1,0,['Practice']
gut microbiota homeostasis,1,1,['Biological Process']
Clostridium sp. BR31,1,1,['microbiota']
certain temperaments,1,0,['personality trait']
Prevotella species,1,0,['microbial species']
reduced functional activation of the hippocampus,1,0,['neurological state']
Illumina Sequencing,1,1,['Method']
dietary microbial metabolites,1,0,['metabolite']
Chronic alcohol overconsumption,1,0,['Condition']
included studies,1,0,['Research Study']
ratios of animal to vegetal foods,1,0,['diet component']
Lactobacillus plantarum R1012,1,0,['Probiotic Strain']
Lunar Palace 1,1,0,['Facility']
pro-inflammatory bacteria,1,1,['Bacteria']
α-diversity indices,1,0,['Measure']
glycan biosynthesis,1,0,['Biological Pathway']
lipopolysaccharide biosynthesis,1,0,['Biological Pathway']
total cholesterol,1,0,['Biochemical Index']
Generalized Anxiety,1,0,['Mental Disorder']
Lactobacillus helveticus R0052,1,0,['Probiotic Strain']
Lunar Palace 365,1,0,['Mission']
microbiota-based countermeasures,1,0,['Countermeasure']
exercise,1,0,['Factor']
fear of cancer recurrence,1,1,['Psychological Condition']
chemotherapy,1,0,['Medical Treatment']
Ruminococcus,1,0,['Microbial Genus']
short-chain fatty acids (SCFAs),1,0,['Biological Molecule']
alternative feed additives,1,0,['Substance']
Microbiota change,1,0,['Microbial community']
16S rDNA surveys,1,0,['Method']
six GI sites,1,1,['Anatomical Location']
influential taxa,1,1,['Biological Entity']
microbiome expression profiles,1,0,['Biological Entity']
genes and pathways,1,0,['Biological Entity']
microbial alteration,1,0,['Therapeutic Strategy']
ratios of pork to pulses,1,0,['diet component']
reduced systemic inflammation,1,1,['Inflammatory Process']
chronic inflammation,1,0,['Inflammatory Process']
Gastrointestinal disorders,1,0,['Disease']
Gut Microbiota Changes,1,1,['Microbiota State']
Proinflammatory Gut Milieu,1,1,['Physiological State']
Short-Chain Fatty Acids (SCFAs),1,0,['Substance']
SCFA-Acylated Starches,1,0,['Substance']
micronutrient treatment,1,0,['treatment']
gut-brain pathways,1,0,['biological pathway']
specific bacteria,1,0,['microbial species']
anxiety/depression,1,0,['Disease']
Patients with PTSD,1,0,['Patient Population']
oral health,1,0,['Health Aspect']
substance use,1,0,['Behavior']
medical history,1,0,['Health Aspect']
early life adversity,1,0,['Factor']
healthy cells,1,0,['Cell type']
future applications of psychobiotics,1,1,['Application']
mental health disorders,1,0,['Disease']
Interdependent Effect on Health,1,2,['Health Outcome']
serum SCFAs,1,0,['Biological Molecule']
Streptococcus,1,0,['Microbial Species']
Parasutterella,1,0,['Microbial Species']
Prevotellaceae NK3B31 group,1,0,['Microbial Species']
butyrate-producing bacteria,1,0,['Microbial Species']
non-tremors predominant phenotype,1,0,['Phenotype']
TCE exposure,1,0,['Exposure']
data generated in study,1,0,['Data']
Corynebacterium,1,1,['Organism']
Gut microbiota composition,1,0,['Measure']
Enterobacteriaceae,1,1,"['Bacterial Family', 'Organism']"
Exopolysaccharide (EPS),1,1,['Biological Molecule']
food production sustainability,1,1,['economic activity']
younger generation,1,0,['demographic']
disability-adjusted life-years (DALYs),1,0,['health metric']
small intestinal microbiome differences,1,0,['Biological Process']
Oral ingestion,1,0,['Action']
gut microbiome alterations,1,1,['Microbial Change']
Disrupted biological pathways,1,0,['Biological Process']
Complement C1q,1,0,['Protein']
diet alterations,1,1,['Dietary Adjustment']
Mixed phenotype,1,0,['Phenotype']
COVID-19 Disease,1,0,['Infectious Disease']
gut microenvironment,1,2,['environment']
Metagenomic Sequencing,1,0,['Method']
change in certain intestinal bacteria,1,0,['Biological Process']
Bacteroides eggerthii,1,0,['Microbial Species']
livestock industry,1,1,['Industry']
social functioning,1,0,['Outcome Measure']
PIGD phenotype,1,0,['Phenotype']
brainstem,1,1,"['brain region', 'anatomical structure']"
shifts in microbiota diversity,1,1,['biological change']
Lactobacillus plantarum,1,1,['Organism']
Gamma-aminobutyric acid (GABA),1,1,['Chemical']
Hypnotic Effects,1,3,['Biological Effect']
Metagenomic analysis,1,0,['Analytical Method']
Trehalose and maltose hydrolase (COG1554),1,0,['Enzyme']
Urease accessory proteins UreE (COG2371),1,0,['Protein']
Escherichia coli,1,0,['Bacterial Species']
Enterobacter cloacae,1,0,['Bacterial Species']
SCFA receptor knockout mice,1,0,['Animal model']
Wheat gluten,1,0,['Food']
Bipolar Disorder,1,1,['Disease']
Toxoplasma gondii,1,0,['Pathogen']
Inflammatory processes,1,0,['Biological Process']
Innate immunity,1,1,['Immune Response']
neuronal stem cell degradation,1,0,['process']
vascular system dysfunction,1,0,['process']
gut microbiome dysbiosis,1,0,['process']
TREM2,1,0,['gene']
C3,1,0,['gene']
Bovine milk casein,1,0,['Food']
KEGG orthology (KO) K01667,1,0,['Gene Orthology']
KEGG orthology (KO) K03781,1,0,['Gene Orthology']
Phylum Firmicutes,1,0,['Taxonomic Group']
38 species,1,0,['Taxonomic Group']
Traumatic Stress,1,0,['Stress Factor']
maternal vaginal microbial transfer,1,0,['transfer']
neurodegenerative diseases (NDs),1,0,['Disease']
Epinephrine,1,0,['Neurotransmitter']
Gut microbiota-hippocampal axis,1,0,['Biological pathway']
synbiotics,1,0,['Therapeutic Agent']
fecal microbiota transplantation,1,0,['Therapeutic Procedure']
Claudin-2,1,0,['Protein']
Gut Barrier Integrity,1,0,['Physiological Function']
Oral SCFA supplementation,1,0,['Therapeutic intervention']
Gut microbiota dysbiosis,1,0,['Microbial community']
Microbiome-gut-brain axis,1,0,['Pathway']
Microbial tryptophan biosynthesis and metabolism pathway (MiTBamp),1,0,['Pathway']
Verrucomicrobiaceae,1,0,['Bacteria']
specific microbes,1,0,['Microbial Species']
microbiome changes,1,0,['biological process']
Immigrant status,1,0,['Demographic Factor']
nutritional strategies,1,1,['strategy']
reactive oxygen species,1,0,['molecule']
loss of chromosome X inactivation,1,0,['process']
Ingesting Lactobacillus plantarum P-8,1,0,['Behavior']
C3aR1,1,0,['gene']
NF-kb,1,0,['gene']
TGFB1&2,1,0,['gene']
Inflammation,1,3,"['Biological Process', 'Condition', 'Physiological State']"
co-abundances,1,0,['Interaction']
SIRT1&6,1,0,['gene']
HMGB1,1,0,['gene']
STING,1,0,['gene']
Mild Metabolic Disorders,1,3,['Disease']
Fecal metagenomes,1,0,['Sample']
TNFA,1,0,['gene']
microbiome-host cross talk pathways,1,0,['Communication Pathway']
Probiotic-induced gut microbiota modulation,1,0,['Process']
Gut microbiomes,1,0,['Organism']
Gut-brain axis,1,0,['Physiological system']
dysregulation,1,0,['process']
microglia genes,1,0,['gene']
telomere attrition,1,0,['process']
decreasing specific microbes,1,1,['Microbial Adjustment']
Low fiber intake,1,0,['Dietary factor']
Gut microbiota diversity,1,0,['Microbial community']
Industrialized nations,1,0,['Geographical region']
microbe-based therapies,1,0,['Therapeutic Approach']
Shannon diversity index,1,0,['Index']
psychiatric disorders,1,5,"['Disease Class', 'disease', 'Condition', 'Disease', 'medical condition']"
Loss of melanin,1,0,['Condition']
crew mental health,1,1,['Health']
"vaginally delivered, fully breastfed infants",1,0,['infant']
transcriptome data,0,1,['Biochemical Data']
moderation DQI-I,0,2,['measurement']
measurement,0,1,['measurement']
Veillonella,0,1,['microbial species']
Christensenellaceae R-7 group,0,1,['microbial species']
Oscillibacter,0,1,['microbial species']
UCG-005,0,1,['microbial species']
dementia,0,1,['Condition']
death,0,1,['Outcome']
pathogenesis of neurodegenerative diseases,0,6,['Pathogenesis']
rising prevalence of neurodegenerative diseases,0,1,['Health Issue']
elderly population,0,1,['Demographic']
viruses,0,1,['microorganism']
fungi,0,1,['microorganism']
neuropsychiatric disorders,0,4,['disease']
oral cavity,0,1,['body part']
nasal passages,0,1,['body part']
hippocampal SYP level,0,2,['Neurobiological Marker']
effect of acetate supplement,0,2,['Therapeutic Effect']
cognitive decline,0,1,['Cognitive Dysfunction']
gluten sensitivity,0,1,['disease']
emphysema,0,1,['disease']
Tourette's syndrome,0,1,['disease']
PTSD,0,1,['disease']
CTE,0,1,['disease']
TBI,0,1,['disease']
suicidal ideation,0,1,['condition']
bacteria,0,1,['microorganism']
anti-inflammatory and regenerative pathways,0,1,['pathway']
chronic disease,0,1,['disease']
kidney disease,0,1,['disease']
liver disease,0,1,['disease']
heart disease,0,1,['disease']
lupus,0,1,['disease']
primary sclerosing cholangitis,0,1,['disease']
atopy,0,1,['disease']
ancient pathways in the brain,0,1,['biological pathway']
chemosensory integration of whole body metabolism,0,1,['biological process']
old concepts of pathogenesis,0,1,['concept']
attention deficit hyperactivity disorder,0,1,['disease']
asthma,0,1,['disease']
cascade of changes,0,1,['biological process']
release of metabolic intermediates,0,1,['biological process']
purinergic signaling,0,1,['biological process']
metabolic syndrome,0,1,['medical condition']
patients with MDD,0,3,['Patient Group']
smoking,0,1,['Behavioral Factor']
alcohol consumption,0,1,['Behavioral Factor']
diet habits,0,1,['Behavioral Factor']
antibiotics,0,1,['Medication']
sample handling,0,1,['Methodological Factor']
wet laboratory methods,0,1,['Methodological Factor']
pathology,0,1,['pathology']
Type 2 diabetes mellitus,0,1,['medical condition']
gut microbial community structure,0,1,['microbial structure']
brain-gut interactions,0,2,['physiological process']
Distinguishing Microbial Differences,0,1,['Analysis']
Predict Functional Changes,0,1,['Analysis']
Therapeutic Strategies,0,1,['Medical Intervention']
altered gut microbiota,0,4,['microbial state']
depletion of anaerobes,0,2,['Biological State']
pathogenic microglial states,0,1,['cellular state']
DAM subsets of microglia,0,1,['cell type']
microglia,0,1,['cell type']
beneficial effects of prebiotics,0,1,['therapeutic effect']
GI symptoms,0,2,"['Symptom', 'symptom']"
microglia activation,0,1,['cellular activity']
PD-like symptoms,0,1,['symptom']
expansion of potential pathobionts,0,2,['Biological State']
self-reported sleep quality,0,1,['Behavioral Measure']
plasma IL-1β,0,1,['Biological Marker']
pathophysiology of mental illnesses,0,1,['disease condition']
acute and chronic insomnia,0,1,['Disease']
inflammatory cytokines production,0,1,['Biological Process']
increased inflammatory cytokines,0,1,['Biological Process']
lower microbial richness and diversity,0,2,['Biological State']
therapeutic targets,0,1,['Therapeutic Target']
gastrointestinal function,0,1,['biological process']
mood modifying effects,0,1,['Physiological Effect']
therapeutic responses,0,1,['Therapeutic Outcome']
adverse responses,0,1,['Adverse Effect']
personalizing antidepressant treatment,0,1,['Treatment Strategy']
high-cited document,0,2,['Publication']
bioavailability,0,1,['Pharmacokinetic Property']
patients with untreated coeliac disease,0,1,['Patient group']
autism-spectrum disorders,0,1,['disease']
stress-related disorders,0,1,['disease']
time to complete the Stroop-CW,0,1,['Cognitive Test Metric']
repeated animal words in 60 s,0,1,['Cognitive Test Metric']
correct answers in 120 s on the Stroop-CW,0,1,['Cognitive Test Metric']
Geographic Location,0,1,['Environmental Factor']
auxiliary diagnosis indicator,0,1,['Diagnostic Tool']
impaired colonic microbial metabolism,0,1,['Condition']
microglial states,0,1,['cellular state']
motor deficits,0,1,['symptom']
α-synuclein aggregation,0,4,"['pathology', 'Pathological Process']"
motor symptoms,0,1,['symptom']
physical health outcomes,0,4,['concept']
mental health outcomes,0,4,['concept']
gut microbial metabolism,0,1,['Physiological process']
higher abundance of Actinobacteria,0,1,['Microbial Abundance']
lower abundance of Firmicutes,0,1,['Microbial Abundance']
lower abundance of Lachnospiraceae,0,1,['Microbial Abundance']
lower abundance of Faecalibacterium,0,1,['Microbial Abundance']
risk of bias,0,1,['Methodological Limitation']
variability in methods,0,1,['Methodological Variation']
other groups,0,1,['Patient group']
small intestinal malabsorption,0,1,['Condition']
publications,0,4,['Publication']
Clostridium difficile colitis,0,1,['infectious disease']
psychophysiological stress reactivity,0,1,['physiological response']
environmental ecology,0,1,['ecological system']
physical health,0,3,"['Health Aspect', 'physiological state']"
Parkinson's disease patients,0,1,['Disease']
pathophysiology of schizophrenia,0,2,['disease']
enhanced oxidative stress,0,1,['Physiological_State']
vagal neurons,0,1,['biological cell']
spinal afferent neurons,0,1,['biological cell']
neuroendocrine-hypothalamic-pituitary-adrenal (HPA) axis,0,1,['biological system']
gut hormones,0,2,"['biological molecule', 'Measurement']"
body mass index (BMI),0,1,['Demographic Factor']
molecular mechanism,0,1,['Biological Process']
gut microbiome composition,0,1,['Biological Entity']
treatment for bipolar disorder,0,1,['Therapy']
microbially-derived neurotransmitters,0,1,['biological molecule']
intestinal barriers,0,1,['biological structure']
brain barriers,0,1,['biological structure']
nutrients,0,1,['biological molecule']
microbiome,0,2,"['Microbial Community', 'biological entity']"
intestinal system,0,1,['biological system']
epithelium,0,1,['biological tissue']
statistics,0,1,['Analytical Method']
candidate biomarkers,0,1,['Biomarker']
downregulation,0,1,['Biological Process']
analyzing gut microbiome data,0,1,['Data Analysis']
samples acquisition,0,1,['Research Method']
statistically significant bacteria,0,1,['Microbial Data']
Bibliometric analysis,0,1,['Research Methodology']
Knowledge-map analysis,0,1,['Research Methodology']
cytokines,0,2,"['biological molecule', 'Protein']"
intestinal metabolite imbalance,0,1,['biological_process']
metabolic profiling,0,1,['method']
bacterial taxa,0,1,['organism']
structural phenotype,0,1,['Biological Phenotype']
functional phenotype,0,1,['Biological Phenotype']
microbiome profiling,0,1,['Biological Analysis']
investigating gut,0,1,['Biological Structure']
associated microbiota,0,1,['Biological Entity']
psychiatric symptoms,0,1,['Symptom']
neurotransmitter levels,0,1,['Biochemical Process']
psychotic disorders,0,1,['Disease']
patients and healthy controls,0,1,['Population Group']
76.82%,0,1,['Accuracy Rate']
70.95%,0,1,['Accuracy Rate']
model accuracy,0,1,['Performance Metric']
development of psychiatric disorders,0,1,['Condition']
psychiatric clinical symptoms,0,1,['symptom']
human disorders,0,1,['Disease']
intestinal microflora disturbances,0,1,['biological_process']
demyelinating disease,0,1,['Disease']
connections between gut-microbiota and brain,0,1,['biological connections']
diseases of the GI tract,0,1,['disease']
irritable bowel syndrome (IBS),0,1,['disease']
nutritional needs,0,1,['Nutritional Requirement']
systemic low-grade inflammation,0,1,['Physiological_State']
health,0,2,"['Health_Status', 'Health Condition']"
dysmetabolism,0,1,['Metabolic_State']
acute patients,0,1,['group']
remission patients,0,1,['group']
environmental information processing,0,1,['biological_process']
organismal systems,0,1,['biological_process']
human diseases,0,1,['disease']
relative abundance of microbiome populations,0,2,['Biological entity']
subdiaphragmatic vagus nerve,0,1,['Anatomical structure']
brain/mental-health-related disease,0,1,['disease']
Dysfunction of the immune system,0,1,['Physiological Dysfunction']
Dysfunction of the endocrine system,0,1,['Physiological Dysfunction']
Dysfunction of the gut,0,1,['Physiological Dysfunction']
Brain,0,1,['Anatomical Structure']
development of diseases,0,1,['disease development']
Htr1a expression levels,0,1,['Gene Expression']
Colorectal cancer treatment efficacy,0,1,['Treatment Efficacy']
Colorectal cancer development,0,1,['Disease Development']
Research trends,0,1,['Research Trends']
Publications,0,2,['Academic Publications']
abnormal gut microbiota composition,0,1,['Condition']
abnormal blood levels of metabolites,0,1,['Condition']
blood levels of metabolites,0,3,['Condition']
Dysfunction of the brain,0,1,['Physiological Dysfunction']
CUS-induced anhedonic behavior,0,1,['Behavior']
Therapeutic approach,0,1,['Therapy']
Mitigating depressive-like behaviors,0,1,['Behavioral Changes']
Anhedonia,0,1,['Symptom']
CUS-induced anhedonic behaviors,0,1,['Behaviors']
Serotonin (5-HT) levels,0,1,['Neurotransmitter Levels']
Medial prefrontal cortex (mPFC),0,1,['Brain Region']
Therapy of mental disorders,0,1,['Therapeutic Measure']
affective disorders,0,2,['Disease']
systematic review,0,1,['Review Type']
alpha diversity,0,1,['Biological Measurement']
Mental disorders,0,2,['Disease']
Treatment research of mental disorders,0,1,['Research Area']
Health condition of the brain-gut axis,0,1,['Physiological Condition']
Prevention of mental disorders,0,1,['Preventive Measure']
CCRA model,0,2,['Experimental Model']
communication between gut-resident bacteria and brain,0,1,['communication']
gut microorganisms,0,1,['microorganisms']
gut physiology,0,1,['physiological process']
neuronal disorders,0,5,['disease']
multiple sclerosis,0,4,"['Neurological Disorder', 'autoimmune disease', 'disease', 'Disease']"
reduced short-chain fatty acid producing bacteria,0,2,['Biological Process']
bidirectional communication system,0,1,['communication system']
relative abundances of Lachnospiraceae,0,2,['Microbial Abundance']
relative abundances of Odoribacter,0,2,['Microbial Abundance']
relative abundances of Helicobacter,0,2,['Microbial Abundance']
intestinal bleeding,0,1,['Condition']
iron deficiency,0,1,['Condition']
chemotherapy-induced myelosuppression,0,1,['Condition']
Fe,0,1,['Chemical Element']
rhEPO,0,1,['Biological Agent']
Vasovagal syncope patients,0,1,['Patient Group']
Frequency of syncope,0,1,['Clinical Symptom']
Systolic pressure reduction,0,1,['Hemodynamic Measure']
Diastolic pressure reduction,0,1,['Hemodynamic Measure']
Mean pressure drop,0,1,['Hemodynamic Measure']
Diastolic pressure drop,0,1,['Hemodynamic Measure']
blood enrichment,0,2,['Therapeutic Effect']
antitumor activity,0,1,['Therapeutic Effect']
interventions,0,1,['therapeutic strategy']
Prader-Willi syndrome,0,2,['syndrome']
treating Prader-Willi syndrome,0,1,['syndrome treatment']
metabolic aspects,0,1,['health aspect']
mental health aspects,0,1,['health aspect']
inflammatory mediators,0,1,['Biological Molecule']
gut-blood barrier,0,1,['Biological Structure']
telomere shortening,0,1,['Biological Process']
relative abundances of Alloprevotella,0,2,['Microbial Abundance']
relative abundances of Escherichia-Shigella,0,2,['Microbial Abundance']
relative abundances of Parabacteroides,0,2,['Microbial Abundance']
relative abundances of Ruminococcaceae_UCG-014,0,2,['Microbial Abundance']
smaller tumor volume,0,1,['Therapeutic Outcome']
Chronic stress-induced anhedonia,0,1,['Symptom']
dopamine,0,1,['Neurotransmitter']
epinephrine,0,1,['Neurotransmitter']
pathogenesis of major depressive disorder,0,1,['Pathogenesis']
MDD patients,0,6,"['Patient Group', 'Patients']"
healthy controls,0,4,"['Control Group', 'group', 'Controls']"
Major depressive disorder (MDD),0,1,['Mental Disorder']
Depressive symptoms,0,1,['Symptoms']
Neurometabolic alterations,0,1,['Alterations']
Therapeutic effects,0,1,['Effects']
relative abundances of Lactococcus,0,2,['Microbial Abundance']
reducing depressive-like behaviours,0,1,['Behaviour']
GABA levels,0,1,['Neurotransmitter Level']
depression- and anxiety-like behaviors,0,1,['Behavioral Disorder']
norepinephrine,0,1,['Neurotransmitter']
glutamate,0,1,['Neurotransmitter']
feature selection,0,1,['Feature Selection']
probiotic,0,2,"['Intervention', 'Probiotic']"
major depressive disorder,0,3,['Disease']
gastrointestinal (GI) tract,0,1,['organ system']
cognitive brain areas,0,1,['brain areas']
neuronal activity,0,1,['biological process']
Microbiota Taxa,0,1,['Biological Entity']
Major Depressive Disorder (MDD),0,1,['Disease']
research quality,0,1,['Research Metric']
anxiety/depression symptom measures,0,1,['Psychological Measurement']
hippocampus,0,2,"['brain region', 'Brain Region']"
antioxidant,0,1,['Effect']
gastrointestinal (GI) symptoms,0,1,['Symptom']
GI tract,0,1,['Anatomical Structure']
postinfection disorders of gut-brain interaction (DGBI),0,1,['Condition']
female gender,0,1,['Demographic Factor']
Listeria monocytogenes,0,1,['Organism']
Biomarker,0,1,['Indicator']
Gut Immunity Abnormalities,0,1,['Condition']
Origanum vulgare,0,1,['ScientificName']
coronary artery disease,0,1,['Disease']
type-2 diabetes mellitus,0,1,['Disease']
brain tissue,0,1,['Anatomical Structure']
increased body weight,0,1,['Physiological Change']
liver fat accumulation,0,1,['Physiological Change']
glucose intolerance,0,1,['Physiological Condition']
prebiotic,0,1,['Effect']
CAD,0,1,['Disease']
T2DM,0,1,['Disease']
Gastrointestinal Problems,0,1,['Condition']
ASD Children,0,1,['Population']
plasma,0,2,['BiologicalFluid']
mitochondrial function,0,1,['BiologicalProcess']
oxidative stress,0,2,"['BiologicalProcess', 'Physiological Process']"
Thymus vulgaris,0,1,['ScientificName']
neurotransmitters,0,4,['Neurotransmitter']
reduced likelihood of MDD,0,1,['Disease Outcome']
liability for MDD,0,1,['Disease Outcome']
depressive-like behaviours,0,2,['Behaviour']
anxiety-like behaviours,0,2,['Behaviour']
short chain fatty acids,0,1,['Metabolite']
kynurenine,0,1,['Metabolite']
cardiac contraction,0,1,['BiologicalProcess']
Antigen Binding,0,1,['Process']
Cancer,0,3,['Disease']
Typically Developing Children,0,1,['Population']
Immune Epitope Database,0,1,['Database']
Groups of Children,0,1,['Population']
Abnormal Gut IgA Levels,0,1,['Condition']
Altered Gut Microbiota Composition,0,1,['Condition']
T or B Cells,0,1,['Cell Type']
Lactobacillus reuteri NK33,0,1,['Bacterial Strain']
Bifidobacterium adolescentis NK98,0,1,['Bacterial Strain']
Interleukin-6,0,1,['Biomarker']
Bifidobacteriaceae,0,1,['Bacterial Family']
MDD group,0,15,"['Group', 'Patient Group']"
HAMD scores,0,1,['Score']
area under the receiver operating characteristic curve of 0.890,0,1,['Performance Metric']
classification,0,1,['Classification']
Cytochrome c protein,0,1,['Protein']
Iron content,0,1,['Chemical']
Signal Transduction Pathways,0,1,['Biological Pathway']
Endocrine and Metabolic Diseases,0,1,['Biological Pathway']
Neurodegenerative Diseases,0,1,['Biological Pathway']
Immune System,0,1,['Biological Pathway']
distinguishing MDD patients from HCs,0,1,['Biomarker Use']
Sleep Quality,0,1,['Health Condition']
Gut Homeostasis Abnormalities,0,1,['Condition']
Negative symptoms of schizophrenia,0,2,['Symptom']
Cognition,0,1,['Cognitive Function']
Excitement,0,1,['Emotion']
Human Self Proteins,0,1,['Protein']
Hematopoietic Stem Cells,0,1,['Cell Type']
Microbiome of the colon,0,1,['Organism']
Cell Membranes,0,1,['Cellular Component']
persistent GI symptoms beyond 1 month after recovery,0,1,['Symptom']
presence of mental health factors,0,1,['Condition']
altered gut motility,0,1,['Physiological Process']
positive impact on various diseases,0,1,['Attribute']
mood regulation,0,1,['Process']
effect of probiotics,0,1,['Effect']
mental well-being,0,1,['Condition']
high cost,0,1,['Attribute']
alterations in the enteroendocrine system,0,1,['Physiological Process']
serotonin metabolism,0,1,['Physiological Process']
long-term sequelae,0,1,['Condition']
severity of COVID-19,0,1,['Severity Level']
anosmia,0,1,['Symptom']
ageusia,0,1,['Symptom']
use of antibiotics,0,1,['Treatment']
hospitalization during the acute illness,0,1,['Medical Event']
Zhe Busong decoction,0,1,['Herbal Medicine']
Ayurvedic polyherbal medicine,0,1,['Medicine Type']
dried fruits,0,1,['Plant Product']
brain health maintenance,0,1,['Health Condition']
visceral hypersensitivity,0,1,['Physiological Process']
gut microbiota dysbiosis,0,3,"['Microbiota', 'Microbial community', 'Physiological Process']"
immune activation,0,1,['Physiological Process']
changes in intestinal permeability,0,1,['Physiological Process']
cognitive resilience,0,1,['Health Outcome']
psychological resilience,0,1,['Health Outcome']
5-hydroxytryptamine (5-HT) receptors,0,1,['Biological Component']
brain-derived neurotrophic factor (BDNF) receptors,0,1,['Biological Component']
antioxidant-related signaling pathways,0,1,['Biological Process']
blood brain barrier (BBB) permeability,0,1,['Physiological Process']
systemic bioavailability,0,1,['Physiological Process']
society,0,1,['Society']
Blood Erythrocytes,0,1,['Cell']
Lymphocytes,0,1,['Cell']
Pathogenesis of Parkinson's Disease,0,1,['Disease']
depressive behaviour,0,1,['Condition']
alternative treatments,0,1,['Treatment']
psychological dysfunction,0,1,['Health Condition']
gut homeostasis,0,2,['Physiological Process']
gut development,0,2,['Developmental Process']
Families,0,2,['Taxonomic Group']
Overgrowth of H<sub>2</sub>S-producing bacteria,0,1,['Organism']
taxonomic differences,0,2,"['Trait', 'Difference']"
tryptophan pathway differences,0,2,"['Trait', 'Difference']"
Reactive Oxygen Species,0,1,['Chemical']
Alpha-synuclein oligomers,0,1,['Protein']
Alpha-synuclein fibrils,0,1,['Protein']
Urate Metabolism,0,1,['Biological Process']
EPS Production,0,2,['Biochemical Activity']
Pentobarbital-induced sleep test,0,1,['Experimental Test']
Polycystic Ovary Syndrome,0,1,['Disease']
Fusobacterium,0,1,['Organism']
Critical care,0,3,['Outcome']
epilepsy,0,3,"['Neurological Disorder', 'disease']"
pathophysiology,0,3,"['Biological Process', 'Physiological Process']"
neurological disorders,0,2,"['Disease Class', 'Disease']"
high risk of side effects,0,1,['Attribute']
low mood,0,1,['Symptom']
poor general interest,0,1,['Symptom']
cognitive dysfunction,0,1,['Symptom']
motor dysfunction,0,1,['Symptom']
published literature,0,1,['Literature']
extensive clinical applications,0,1,['Attribute']
gut barrier,0,1,['Anatomical Structure']
Progression of PCOS,0,1,['Disease Progression']
Profiling Fecal Microbiota,0,1,['Biological Analysis']
Gene Expression Profiling,0,1,['Biological Analysis']
Ruminococcus torques,0,1,['Microbial Species']
Psychobiotic,0,1,['Probiotic Type']
Immune Dysfunction,0,1,['Condition']
Inflammatory Conditions,0,1,['Disease State']
Respiratory Infections,0,1,['Disease']
Metabolomic Pathways,0,1,['Process']
Mental Health,0,2,"['Condition', 'Health Condition']"
Coprococcus comes,0,1,['Microbial Species']
Megasphaera elsdenii,0,1,['Microbial Species']
Acidaminococcus intestini,0,1,['Microbial Species']
Barnesiella viscericola,0,1,['Microbial Species']
35 elevated genes,0,1,['Gene Expression']
37 downregulated genes,0,1,['Gene Expression']
Function in Host Immune System Homeostasis,0,1,['Biological Function']
Degeneration of dopaminergic neurons,0,1,['Pathological process']
α-synuclein accumulation,0,1,['Pathological process']
Neuroinflammation,0,1,['Pathological process']
Colonic Permeability,0,1,['Condition']
Tight Junction Proteins,0,1,['Protein']
Inflammatory Cytokines,0,1,['Protein']
Normalization of Beneficial Microbes,0,1,['Process']
enteric nervous system function,0,2,['Physiological Process']
prediabetes,0,1,['Medical Condition']
placebo,0,1,['Intervention']
change in HbA1c,0,1,['Measurement']
anthropometry,0,1,['Measurement']
body composition,0,1,['Measurement']
glucose tolerance,0,2,['Physiological Process']
Lacticaseibacillus rhamnosus HN001,0,1,['Probiotic']
lipids,0,1,['Measurement']
hunger hormones,0,1,['Measurement']
liver enzymes,0,1,['Measurement']
calorie intake,0,1,['Measurement']
macronutrient intake,0,1,['Measurement']
quality of life,0,1,['Measurement']
hunger,0,1,['Measurement']
global health,0,1,['Concept']
mood,0,2,"['Behavioral Entity', 'Measurement']"
eating behavior,0,1,['Measurement']
43 ± 2.7 mmol/mol,0,1,['Measurement Value']
41 ± 2.3 mmol/mol,0,1,['Measurement Value']
weight loss,0,2,['Physiological Change']
probiotic group,0,2,['Group']
psychological benefits,0,1,['Outcome']
glucoregulatory markers,0,1,['Measurement']
lower Bifidobacteria,0,1,['Bacteria']
glycemic improvement,0,1,['Physiological Change']
pathogenesis,0,1,['Pathogenesis']
clinical picture,0,1,['Clinical Picture']
increase in Bacteroides,0,1,['Bacteria']
decrease in Firmicutes,0,1,['Bacteria']
decrease in Firmicutes / Bacteroidetes ratio,0,1,['Ratio']
decrease in Bifidobacteria,0,1,['Bacteria']
Neuroinflammatory Disorders,0,1,['Disease']
Gut-Lung Axis,0,1,['Physiological Axis']
increased tryptophan transportation,0,1,['transport process']
Immune System Activation,0,1,['Biological Process']
Symbiotic Relationship,0,1,['Relationship Type']
higher Bacteroides,0,1,['Bacteria']
lower Firmicutes,0,1,['Bacteria']
lower Firmicutes / Bacteroidetes ratio,0,1,['Ratio']
Lachnospiraceae NK4A136 group,0,1,['Organism']
Faecalibacterium prausnitzii,0,2,"['Organism', 'Species']"
Endolysosomal deficits,0,1,['Pathological process']
Drinking water,0,1,['Environmental medium']
Chronic disease risk,0,1,['Health condition']
Idiopathic PD,0,1,['Disease']
Threatening condition,0,1,['Condition']
Metabolic health,0,1,['Biological Process']
Akkermansias,0,1,['Bacteria']
Desulfovibrio,0,1,['Bacteria']
glucose homeostasis,0,1,['Physiological Function']
Muscular health,0,1,['Biological Process']
Clinical outcomes,0,1,['Outcome']
Microbiota diversity,0,1,['Measure']
Microbiota composition,0,1,['Measure']
Differential abundance,0,1,['Measure']
16S RNA method,0,1,['Method']
psychiatric comorbidities,0,1,['Comorbidity']
Antidepressant effect,0,1,['Effect']
Chronic Unpredictable Mild Stress (CUMS) model,0,1,['Experimental Model']
ASD,0,4,"['disorder', 'disease']"
ADHD,0,1,['disease']
serum metabolism,0,1,['Metabolism']
emotional mood,0,1,['Emotional State']
antibiotic growth promotants (AGPs),0,1,['Substance']
feed additives,0,1,['Substance']
colonization by pathogens,0,1,['Biological Process']
nutrient utilization,0,1,['Biological Process']
community composition,0,1,['Biological Entity']
clinical symptoms,0,1,['Clinical Measure']
Hamilton anxiety scale scores,0,1,['Clinical Measure']
pathogenic mechanism of MDD,0,1,['Pathogenic Mechanism']
three key timepoints,0,1,['Timepoint']
IL-17,0,1,['Protein']
arthropathy,0,1,['Disease Condition']
physiologic systems,0,1,['Biological System']
bone metabolism,0,2,['Biological Process']
skeletal destruction,0,1,['Pathological Condition']
joint destruction,0,2,['Pathological Condition']
psoriatic arthritis,0,1,['Disease']
metabolomics,0,1,['Method']
taxonomic abundances,0,1,['Biological Entity']
other taxa,0,1,['Biological Entity']
cell wall biogenesis,0,1,['Biological Process']
impact of AGPs,0,1,['Substance']
composition and function of chicken gut microbiome,0,1,['Biological Entity']
two different diets,0,1,['Diet']
AGP treatments,0,1,['Treatment']
drive future studies,0,1,['Research Study']
energy metabolism,0,1,['Biological Process']
amino acid metabolism,0,1,['Biological Process']
nucleotide metabolism,0,1,['Biological Process']
metabolic flux,0,1,['Biological Process']
bacterial growth,0,1,['Biological Process']
host,0,1,['Organism']
metatranscriptomics analyses,0,1,['Method']
ELISA kit,0,1,['Method']
MDD clinical indicators,0,1,['Clinical Measure']
decrease in Lactobacilli,0,1,['Bacteria']
participants with chemotherapy history,0,6,['Human Population']
first-episode depression,0,1,['Disease']
site-associated taxa,0,1,['Biological Entity']
age-associated taxa,0,1,['Biological Entity']
diet-associated taxa,0,1,['Biological Entity']
cancer,0,2,['disease']
molecular dysfunctions,0,1,['process']
joint pathology,0,1,['Pathological Condition']
healing,0,1,['Biological Process']
AI-related musculoskeletal pathology,0,1,['Pathological Condition']
regenerative medicine,0,2,['Medical Field']
Altered phylogenetic compositions,0,1,['Biological Process']
Pathogenesis,0,2,"['Process', 'Disease Process']"
gut health,0,1,['Concept']
poultry production,0,1,['Industry']
environment,0,1,['Environmental Factor']
age-associated diseases,0,1,['disease']
neurodegenerative diseases,0,10,"['Disease', 'disease']"
inflammatory diseases,0,1,['disease']
metabolic diseases,0,1,['disease']
cardiovascular diseases,0,2,['disease']
human functioning,0,1,['Physiological Function']
metabolic pathways,0,2,"['biological process', 'Biological Pathway']"
mechanical pathways,0,1,['Biological Pathway']
immunological pathways,0,1,['Biological Pathway']
neurologic pathways,0,1,['Biological Pathway']
throughout lifetimes,0,1,['Time Period']
community-based metabolic modeling,0,1,['Method']
mechanistic impact of dietary regimes,0,1,['Concept']
individually unique,0,1,['Characteristic']
in physical and mental health,0,1,['Health Aspect']
fat content,0,1,['Nutritional Component']
sugar content,0,1,['Nutritional Component']
TNF-a,0,1,['Protein']
IL-6,0,2,"['Cytokine', 'Protein']"
genetics,0,1,['Genetic Factor']
individual microbiomes,0,1,['Microbiome']
gut Bifidobacterium,0,1,['bacterial population']
mental disorders,0,2,"['Disease', 'disease']"
pathophysiological mechanisms,0,1,['biological process']
prosocial behavior,0,1,['behavioral trait']
maternal gut microbiota,0,1,['biological structure']
neurodevelopmental outcomes,0,1,['outcome']
flu and autism spectrum disorder,0,1,['disorder']
Lachnospiraceae family,0,1,['bacterial family']
Chronic Restraint Stress-Induced Neurobehavioral Deficits,0,1,['Condition']
Gut Barrier Deficits,0,1,['Condition']
serum metabolome,0,1,['Metabolome']
systemic inflammation,0,3,"['Inflammation', 'Condition', 'Inflammatory Process']"
Metabolic Syndrome,0,1,['Disease']
Risk of Comorbidities,0,1,['Health Risk']
Increased Risk of Comorbidities,0,1,['Health Risk']
bifidobacterial populations,0,1,['bacterial population']
Psychological Function,0,1,['Function']
Intestine-Targeted Release,0,1,['Process']
Depression-Like Behaviors,0,1,['Condition']
Excessive Corticosterone Production,0,1,['Process']
Depression-like behavior,0,1,['Behavior']
Neurotransmitter levels,0,1,['Biochemical Parameter']
Gut microbiota structure,0,1,['Microbial Community']
Amino acid metabolic functions,0,1,['Metabolic Process']
autism spectrum disorder,0,4,"['disorder', 'developmental disorder']"
Synapses,0,1,['Anatomical Structure']
Digestion,0,1,['Biological Process']
Gut permeability,0,1,['Physiological Process']
Behavior,0,1,['Behavioral Process']
Core bacterial compositions,0,1,['Biological Entity']
Inefficient gluten digestion,0,1,['Condition']
Host Health,0,1,['Condition']
Endothelial barrier permeability,0,1,['Physiological Process']
Translocation of gut bacteria,0,1,['Biological Process']
Inflammatory GI environment,0,1,['Condition']
Activation of complement C1q,0,1,['Biological Process']
Autoimmune disorders,0,1,['Disease']
Enteropathic celiac disease,0,1,['Disease']
Non-celiac food sensitivities,0,2,['Condition']
Humoral immunity to food antigens,0,1,['Immune Response']
Gut Dysbiosis,0,1,['Microbiota State']
Proinflammatory Gut Environment,0,1,['Physiological State']
Microbiota Dysbiosis,0,1,['Microbiota State']
Inflammatory Gut Milieu,0,1,['Physiological State']
Mucosal Barrier Integrity,0,1,['Physiological Function']
Gut Microbiota Homeostasis,0,1,['Microbiota State']
Proinflammatory Milieu,0,1,['Physiological State']
Dysbiotic Gut Microbiota,0,1,['Microbiota State']
bony tissue,0,1,['Anatomical Structure']
cartilaginous tissue,0,1,['Anatomical Structure']
stress and anxiety symptoms,0,1,['Condition']
human intestinal microbiota,0,1,['Organism']
mental health problems,0,1,['Condition']
stress and anxiety,0,1,['Condition']
probiotic and placebo groups,0,1,['Group']
progression of age-related brain diseases,0,1,['process']
diet changes,0,1,['Dietary Adjustment']
rebalancing microbial diversity,0,1,['Microbial Adjustment']
increased gut permeability,0,1,['Physiological Condition']
systemic lupus erythematosus,0,1,['Disease']
irritable bowel disease,0,1,['Disease']
rheumatoid arthritis,0,2,"['disease', 'Disease']"
cells of bone,0,1,['Cell Type']
cells of cartilage,0,1,['Cell Type']
Bifidobacterium adolescentis,0,1,['Organism']
Bifidobacterium longum,0,1,['Organism']
Fecalibacterium prausnitzii,0,1,['Organism']
Roseburia faecis,0,1,['Organism']
onset and progression of neurological disorders,0,1,['Disease Process']
novel therapeutic strategies,0,1,['Therapeutic Strategy']
autism spectrum disorders,0,3,"['Neurological Disorder', 'disease']"
stroke,0,1,['Neurological Disorder']
migration of peripheral inflammatory factors,0,1,['Pathological Process']
Fusicatenibacter saccharivorans,0,1,['Organism']
diversity of neurotransmitter-synthesizing/consuming SGBs,0,1,['Organism']
gamma-aminobutyric acid,0,2,['Chemical']
arachidonic acid,0,1,['Chemical']
sphingomyelin,0,1,['Chemical']
stress/anxiety alleviation,0,1,['Condition']
placebo group,0,2,['Group']
breach of intestinal barrier,0,1,['Pathological Process']
changes in gut microbiome,0,1,['Biological Process']
augmented behavioral outcomes,0,1,['Outcome']
relieving stress-related symptoms,0,1,['Condition']
microbial diversity changes,0,1,['Process']
gut metagenome modulations,0,1,['Process']
intestinal inflammation,0,1,['Pathological Process']
gastric disturbances,0,1,['Symptom']
Coliform,0,1,['Organism']
gene dysfunction,0,1,['process']
preventive benefits,0,1,['benefit']
therapeutic benefits,0,1,['benefit']
neurodegeneration,0,11,"['process', 'Biological Process', 'Condition']"
anti-inflammatory,0,1,['Effect']
model of colitis,0,1,['Disease Model']
gut inflammation,0,1,['Pathological Process']
brain functional elements,0,1,['Organ part']
mouse model,0,1,['Animal model']
impaired cognition,0,1,['Cognitive function']
deficits in object location memory,0,1,['Cognitive function']
deficits in temporal order memory,0,1,['Cognitive function']
deficits in daily living activities,0,1,['Behavior']
aging brain,0,1,['Organ']
decrease in dietary fiber intake,0,1,['Behavior']
inflammatory outcomes,0,1,['Outcome']
Bacteroidaceae,0,1,['Taxonomic Family']
Porphyromonadaceae,0,1,['Taxonomic Family']
Rikencellaceae,0,1,['Taxonomic Family']
S24-7,0,1,['Taxonomic Family']
colonic pro-inflammatory cytokine expression,0,1,['Pathological Process']
impact of LPS plus paraquat,0,1,['Toxic Exposure']
microglial morphology,0,1,['Pathological Process']
lifestyle,0,1,['Lifestyle Factor']
antibiotic or nonantibiotic drug use,0,1,['Drug Use']
circulating lipocalin-2,0,1,['Protein']
loss of substantia nigra dopamine neurons,0,2,['Neurological Process']
astrocytic and cytoskeleton remodeling,0,2,['Pathological Process']
systemic inflammatory events,0,1,['Pathological Process']
brain-gut changes,0,1,['Pathological Process']
neuro-immune communication,0,1,['Biological Process']
diagnostic microbial biomarkers,0,1,['Diagnostic Tool']
health benefits in neurological disorders,0,5,['Health Outcome']
maturation and development of the immune system,0,1,['Biological Process']
central nervous system,0,1,['Biological System']
gastrointestinal tract (GIT) system,0,1,['Biological System']
essential metabolic pathways,0,1,['Biological Process']
host genetic predisposition,0,1,['Genetic Factor']
environmental factors,0,1,['Environmental Factor']
neurotransmitter synthesis,0,1,['Biochemical Process']
gut microbiota-brain axis,0,1,['Physiological Pathway']
behaviors,0,1,['Behavior']
astrocyte activation,0,1,['Cellular Process']
2-DG uptake,0,1,['Physiological Process']
ATP,0,1,['Biochemical Substance']
diet-associated cognitive decline,0,1,['Disease']
bipolar disorder with current major depressive episode (BPD),0,1,['Disease']
Antimicrobial Responses,0,1,['Physiological Response']
Increase in Intestinal Expression of Claudin-2,0,1,['Gene Expression']
Tight Junction Protein,0,1,['Protein Type']
Gut Homeostasis,0,1,['Physiological State']
activation,0,1,['Cellular Process']
glycometabolism,0,1,['Metabolic Process']
animal behaviors,0,1,['Behavior']
HPA axis dysfunction,0,1,['Physiological Dysfunction']
differential infant microbiota composition,0,1,['composition']
microbiome composition,0,2,"['biological entity', 'Microbiome']"
colonic microbiome,0,1,['Microbiome']
Increase in Intestinal Expression of Epinephrine,0,1,['Neurotransmitter Expression']
Stress-Induced Neurotransmitter,0,1,['Neurotransmitter Type']
Claudin-2 Expression,0,2,['Gene Expression']
Transepithelial Electrical Resistance,0,3,['Physiological Measurement']
Mucin Homeostasis,0,1,['Physiological State']
Western populations,0,1,['Population']
cognition,0,1,['Cognitive function']
glucose-1-phosphate,0,1,['Biochemical Substance']
brain-derived neurotrophic factor,0,1,['Protein']
multiple sclerosis (MS),0,1,['Disease']
neuromyelitis optica (NMO),0,1,['Disease']
amyotrophic lateral sclerosis (ALS),0,1,['Disease']
Bifidobacteria,0,1,['bacteria']
BPD patients from HCs,0,1,['Patient Group']
Gastrointestinal Tract,0,1,['Anatomical Structure']
Gastric Cancer,0,1,['Disease']
Esophageal Cancer,0,1,['Disease']
Carcinogenesis,0,1,['Biological Process']
Bacteria,0,1,['Microbial Entity']
gut microbiota at genus level,0,1,['Taxonomic Group']
area under the receiver operating characteristic curve of 0.997,0,1,['Performance Metric']
effects of bacteria on host,0,2,['Effect']
reproducibility,0,1,['Property']
Alzheimer's disease (AD),0,1,['Disease']
multiple system atrophy (MSA),0,2,['Disease']
mice with short-term FD diet,0,1,['Animal model']
cognitive outcomes,0,1,['Cognitive function']
synaptic proteins,0,1,['Protein']
synapses,0,1,['Anatomical structure']
Maltotriose,0,1,['Carbohydrate']
Fecal metagenome-wide sequencing,0,1,['Genomic Technique']
Serum metabolomics profiling,0,1,['Metabolomic Technique']
Primary genus,0,1,['Genus']
Clusters of orthologous groups of protein (COG) categories,0,1,['Protein Grouping']
comparability of data,0,1,['Property']
disease,0,1,['Disease']
disease group,0,1,['Disease Group']
intestinal barrier,0,1,['Organ part']
short-chain fatty acid production,0,1,['Biochemical process']
study SCFA role,0,2,['Biological process']
linking gut microbiota and cognitive impairment,0,1,['Pathophysiological process']
gut microbiota-hippocampal axis,0,1,['Biological pathway']
cognitive deficits,0,1,['Cognitive function']
Depression patients,0,1,['Patient Group']
IBS-D,0,1,['Disease']
25 BPD patients,0,1,['Patient Group']
28 healthy controls (HCs),0,1,['Control Group']
microbial biomarkers,0,1,['Biomarker']
BPD patients,0,3,['Patient Group']
Hospitalization,0,1,['Treatment']
Mucispirillum,0,1,['Organism']
Porphyromonas,0,1,['Organism']
controls,0,1,['Group']
Anandamide,0,1,['Neuroactive Compound']
Clinical differences,0,1,['Clinical Phenotype']
Brain-gut disorder,0,1,['Disease State']
seeding the microbiota,0,1,['process']
infant faecal microbiota,0,1,['microbiota']
IBS-D patients,0,2,['Patient Group']
BPD group,0,2,['Patient Group']
BPD,0,7,['Disease']
Antidepressant-like Activity,0,1,['Therapeutic Effect']
Inflammation-Brain Axis,0,1,['Physiological Mechanism']
gut microbiota establishment,0,1,['Physiological Process']
infant microbiota,0,1,['microbiota']
mother's microbiota,0,1,['microbiota']
seeding infant stool microbiota,0,2,['process']
infant gut microbiota,0,1,['microbiota']
Isomaltose,0,1,['Carbohydrate']
digestion,0,1,['Physiological Process']
nutrient absorption,0,1,['Physiological Process']
immune system development,0,1,['Physiological Process']
modulation of host metabolism,0,1,['Physiological Process']
inflammatory bowel disease,0,2,['Disease']
Stress Group,0,1,['Experimental Group']
Lactobacillus Abundance,0,1,['Microbial Population']
Immune Changes,0,1,['Physiological Response']
child internalising behaviour,0,2,['Behaviour']
formation of neuroactive compounds,0,1,['Chemical']
food-mood relationship,0,2,['Health']
Hippocampus,0,3,['Brain Region']
Non-Stress Group,0,1,['Control Group']
Stress-Related Disorders,0,1,['Condition']
Multi-Strain Probiotics Treatment,0,3,['Therapeutic Agent']
Anxiety- and Depressive-like Behaviors,0,4,['Behavioral Deficits']
cognitive function,0,4,"['Biological Process', 'Health Outcome', 'biological process']"
gastrointestinal disorders,0,1,['Disease']
chronic enteropathy,0,1,['Disease']
food allergies,0,1,['Disease']
ulcerative histiocytic colitis,0,1,['Disease']
future health trajectory,0,1,['Health Outcome']
behaviour,0,3,"['Process', 'behavioural process']"
16S rRNA amplicon sequencing,0,1,['Method']
Behavioral Deficits,0,2,['Condition']
diagnosis,0,1,['diagnostic process']
study metabolic pathways,0,1,['biological process']
therapeutic interventions,0,1,['Medical Treatment']
strategies to enhance well-being,0,1,['Health Strategy']
Host metabolism,0,2,['Biological Process']
Brain-gut axis,0,2,['Physiological System']
neurological conditions,0,1,['Disease']
non-tremor PD subtype,0,1,['Disease Subtype']
Sex,0,1,['Demographic Factor']
Age,0,1,['Demographic Factor']
BMI,0,1,['Health Metric']
Illness Duration,0,1,['Health Metric']
Daily Dose Of Escitalopram,0,1,['Medication Dosage']
Increased Alpha Biodiversity,0,1,['Biological Outcome']
Escitalopram Administration,0,1,['Medication Administration']
offspring brain development,0,1,['Process']
biomarker,0,1,['diagnostic tool']
brain development,0,1,['Process']
Anxiety,0,1,['Mental Disorder']
Probiotic interventions,0,1,['Intervention']
motor symptom severity,0,1,['Clinical Measurement']
plasma concentrations of IFNγ,0,2,['Biochemical Measurement']
plasma concentrations of TNFα,0,1,['Biochemical Measurement']
Depressive-like symptoms,0,2,['Symptom']
immune system's attempt to eradicate pathogens,0,1,['Biological process']
immune system's response to pathogens,0,1,['Biological process']
ATP production,0,1,['Energy production']
comparing gut microbiota,0,1,['comparison']
schizophrenia patients,0,10,['patient group']
mothers of children with normative behaviour,0,2,['Mother']
decreased child internalising behaviour,0,1,['Behaviour']
physical and mental health,0,3,['Health Condition']
Tibetan Buddhist monks,0,1,['Human Group']
neighboring residents,0,1,['Human Group']
constipation,0,5,['gastrointestinal symptom']
total GI symptoms,0,2,['gastrointestinal symptom']
Intestinal microbiota,0,1,['Biological Entity']
new avenues for treatment development,0,1,['Treatment approach']
Major depressive disorder,0,1,['Disease']
schizophrenia patients and healthy controls,0,2,['patient and control groups']
16S rRNA Sequencing,0,1,['Technique']
Escitalopram,0,1,['Medication']
After Six Weeks,0,2,['Time Period']
Psychiatric Hospital Setting,0,1,['Location']
Major Depressive Disorders,0,1,['Mental Disorder']
Antibacterial Activity,0,1,['Activity']
Intestinal Bacteria,0,1,['Organism']
meditation and control groups,0,1,['Human Groups']
meditation group,0,9,['Human Group']
manned deep-space exploration,0,1,['Activity']
long-term closed environments,0,1,['Environment']
maintain and improve psychological health,0,1,['Action']
psychological changes,0,1,['Change']
correlation between gut microbiota and psychological changes,0,1,['Correlation']
with excellent performance,0,1,['Attribute']
diagnostic clinical interview,0,1,['Methodology']
monks and control subjects,0,1,['Human Groups']
reduced risk of anxiety,0,1,['Health Condition']
reduced risk of depression,0,1,['Health Condition']
reduced risk of cardiovascular disease,0,1,['Health Condition']
immune function,0,2,"['Biological Process', 'Biological Function']"
differential intestinal microbial communities,0,1,['Biological Entity']
function of faecal microbiota,0,1,['Biological Function']
peer-reviewed journals,0,1,['Publication']
scientific conferences,0,1,['Event']
psychosomatic conditions,0,1,['Health Condition']
well-being,0,1,['Health Condition']
microbiota function,0,3,['Biological Process']
160 females,0,1,['Sample']
comprehensive questionnaires,0,1,['Methodology']
anthropometrics,0,1,['Methodology']
plasma level of TNFα,0,1,['Biochemical Measurement']
patients with PD,0,2,['Patient Group']
collection of saliva samples,0,1,['Methodology']
urine samples,0,1,['Sample']
hair samples,0,1,['Sample']
systems biology approach,0,1,['Methodology']
nuclear MR spectroscopy,0,1,['Technique']
University of Melbourne Human Research Ethics Committee,0,1,['Institution']
many diseases,0,1,['Disease category']
informed consent,0,1,['Action']
host mood,0,1,['Biological Process']
gastrointestinal functioning,0,1,['Biological Process']
functional gastrointestinal disorders,0,1,['Disease']
females with anxiety/depression,0,2,['Population']
females with IBS,0,2,['Population']
future efforts to develop microbiota-based countermeasures,0,1,['Countermeasure']
human mood,0,1,['Health']
amount of neuroactive compounds,0,1,['Chemical']
profile of neuroactive compounds,0,1,['Chemical']
investigation of diet effects,0,1,['Research']
Depressive behaviors,0,1,['Behavior']
Lactobacillaceae,0,2,['Bacterial Family']
plants,0,1,['Organism']
microorganisms,0,1,['Organism']
Immune system,0,1,['Biological system']
scavenging reactive oxygen species,0,1,['Biological process']
absorbing metals,0,1,['Biological process']
thermal regulation,0,1,['Biological process']
drug uptake,0,1,['Biological process']
innate immune system functions,0,1,['Biological process']
redox,0,1,['Biological process']
human health,0,2,"['Health Outcome', 'Health']"
samples,0,1,['Sample']
pro-inflammatory substances,0,1,['Substance']
anti-inflammatory substances,0,1,['Substance']
inflammation-related genes,0,1,['Gene']
larger sample,0,9,['Population']
heart,0,1,['Tissue type']
arteries,0,1,['Tissue type']
ovaries,0,1,['Tissue type']
cells,0,1,['Cell type']
energy supply from melanin,0,1,['Energy supply']
energy transduction,0,1,['Biological process']
serotonin,0,1,['Chemical']
kynurenic acid,0,1,['Chemical']
tryptamine,0,1,['Chemical']
taurine metabolism,0,1,['Pathway']
cortisol metabolism,0,1,['Pathway']
bladder,0,1,['body part']
vagina,0,1,['body part']
gastrointestinal tract,0,1,['body part']
neurodegenerative disorders,0,3,"['disease', 'disease condition']"
energy supply of cells,0,1,['Energy supply']
inability to sustain immune system defenses,0,3,['Biological process']
inability to remove plaques,0,3,['Biological process']
electromagnetic radiation,0,1,['Energy source']
mammalian mental health during space flight,0,1,['Health']
aspartic acid,0,1,['Chemical']
development,0,1,['process']
progression,0,1,['process']
periodontitis,0,1,['disease']
lungs,0,1,['body part']
gut,0,3,"['Anatomical Structure', 'biological organ', 'body part']"
skin,0,1,['body part']
moon,0,1,['Location']
Mars,0,1,['Location']
neuropsychiatric treatments,0,1,['Treatment']
positive regulatory effect,0,1,['Effect']
mechanism of potential psychobiotics on mood,0,1,['Mechanism']
maintenance and improvement of mental health,0,1,['Outcome']
long-term closed environment,0,1,['Environment']
better understanding the role of the gut microbiome,0,1,['Understanding']
conduct disorders,0,1,['disease']
eating disorders,0,1,['disease']
reduction in dietary quality,0,1,['diet component']
older generation,0,1,['demographic']
changes in diet composition,0,1,['diet component']
food production,0,1,['economic activity']
DALY percent,0,3,['health metric']
depressive disorders,0,1,['disease']
family Enterobacteriaceae,0,1,['Taxonomic Group']
coliform genera Escherichia,0,1,['Taxonomic Group']
human ageing,0,1,['Biological Process']
entire gut,0,1,['Anatomical Structure']
host metabolism,0,1,['Biological Process']
older subjects,0,2,['Population Group']
other dementias,0,1,['disease']
headache disorders,0,1,['disease']
anaerobes,0,1,['Biological Characteristic']
coliform genera Klebsiella,0,1,['Taxonomic Group']
chronologic age,0,1,['Measurement']
number of medications,0,1,['Measurement']
number of concomitant diseases,0,1,['Measurement']
number of medications alone,0,2,['Measurement']
251 subjects,0,1,['Population Group']
18-80 years,0,1,['Age Range']
Bacteroides uniformis,0,1,['Species']
Roseburia inulinivorans,0,1,['Species']
Eubacterium rectale,0,1,['Species']
butyric acids,0,1,['Chemical']
propionic acids,0,1,['Chemical']
number of diseases alone,0,3,['Measurement']
chronologic age alone,0,4,['Measurement']
increasing chronologic age,0,1,['Measurement']
disease burden,0,2,['health metric']
human behavior,0,1,['Behavioral Entity']
gut microbiota disorder,0,1,['Biological Disorder']
protective function of intestinal barrier,0,1,['Physiological Function']
alpha diversity indices,0,1,['Biological Measurement']
13 taxonomic biomarkers,0,1,['Biomarker']
altered mitochondrial and cellular macromolecule content,0,1,['biological structure']
mitocellular hormesis,0,1,['biological process']
brains,0,1,['body part']
patients with Alzheimer's disease,0,1,['disease']
biological mechanisms,0,1,['concept']
biomarkers,0,3,"['Biomarker', 'concept', 'Biomarkers']"
microbiota-targeted interventions,0,1,['treatment']
immune system,0,2,['biological system']
human homeostasis,0,1,['biological process']
low-level inflammation,0,1,['Physiological State']
streptozotocin (STZ)-induced T1D mice,0,1,['Experimental Model']
skin inflammation,0,1,['Condition']
serum hormone production,0,1,['Biological Process']
skin lipids,0,1,['Biological Molecule']
expression of lipid metabolism-related genes,0,1,['Gene Expression']
ratio of Bacteroidetes to Firmicutes,0,1,['Microbial Ratio']
relative abundance of Staphylococcus,0,1,['Microbial Abundance']
acne,0,1,['Disease']
KEGG pathways,0,1,['Biological Pathway']
cognitive impairment,0,6,"['Cognitive Dysfunction', 'Disease', 'Health Condition']"
depletion of acetate-producing bacteria,0,1,['Microbial Depletion']
reduction of synaptophysin (SYP) in the hippocampus,0,1,['Neurobiological Change']
learning and memory impairments,0,1,['Cognitive Dysfunction']
gut function,0,1,['BiologicalProcess']
incidence of type 1 diabetes mellitus (T1D),0,1,['Disease']
cognitive functions,0,3,"['Health Aspect', 'Physiological Function']"
RYGB and SG,0,1,['surgical procedures']
mental states,0,1,['condition']
gut-brain microbiota axis,0,1,['biological system']
mood disorders,0,2,"['condition', 'disease']"
mental deterioration,0,1,['condition']
larger group of patients,0,1,['group']
different probiotic doses,0,1,['intervention']
malfunctioning of neurons,0,1,['Physiological Process']
medicinal plants,0,1,['Plant']
metabolic profiles,0,1,['Health Aspect']
reduction in HRSD,0,1,['measurement']
Mental health,0,1,['Health Condition']
reduction in BDI,0,1,['measurement']
Psychosis,0,2,['Disease']
depressive symptoms,0,1,['condition']
eating habits,0,1,['behavior']
microbiome studies,0,1,['Study Type']
metabolome,0,1,['Biochemical Data']
lipidome,0,1,['Biochemical Data']
nutrient uptake,0,1,['Physiological Process']
lipid metabolism,0,1,['Physiological Process']
gut microbiome-brain axis,0,1,['Biological System']
pathogenesis of NDD,0,1,['Pathogenesis']
prevention of NDD,0,2,['Application']
host metabolic phenotypes,0,1,['Physiological State']
neoplasms,0,1,['disease']
health outcomes,0,2,['health metric']
"chemical, physical, or biological threats",0,1,['stimulus']
burden of diseases,0,10,['health metric']
food intake,0,1,['Diet']
genetic variants,0,1,['Genetic Data']
epigenetic data,0,1,['Epigenetic Data']
enteric nervous system,0,1,['biological system']
endocrine system,0,1,['biological system']
inflammatory disorders,0,1,['disease']
autoimmune disorders,0,1,['disease']
metabolic disorders,0,1,['disease']
behavioral disorders,0,1,['disease']
cognitive disorders,0,1,['disease']
depletion of SCFA-producing bacteria,0,2,['Biological State']
Brain function,0,2,"['Biological Process', 'Physiological Function']"
Immunity,0,2,"['Physiological Function', 'Biological Function']"
Metabolic pathways,0,1,['Biological Pathway']
Symptom severity,0,1,['Health Condition']
gastrointestinal diseases,0,1,['MedicalCondition']
Human health,0,2,['Health Condition']
DQI-I adequacy,0,2,['measurement']
pain-related disorders,0,1,['disease']
brain health,0,1,['Health Aspect']
progression to full-blown disease,0,1,['Disease Progression']
low-grade inflammation,0,1,['Condition']
anomalies in lipid metabolism,0,1,['Condition']
brain function,0,5,"['BiologicalProcess', 'Organ function', 'biological process']"
depression,0,6,"['mental disorder', 'MedicalCondition', 'Disease', 'Psychiatric Disorder', 'Mental Disorder']"
anxiety,0,4,"['Condition', 'Disease', 'MedicalCondition', 'Psychiatric Disorder']"
Brain structure,0,1,['Anatomical Structure']
irreversible loss of neurons,0,1,['Physiological Process']
organ transplant biology,0,1,['biological process']
diabetes,0,1,['disease']
lipid profiles,0,1,['Health Aspect']
decreased risk of dementia,0,1,['Health Outcome']
decreased risk of Alzheimer's disease,0,1,['Health Outcome']
neuroprotective effects,0,1,['Effect']
humans,0,1,['Population']
